Research At a Glance
- Research Category
- Dermal, Immune & Tissue Repair Research
- Peptide Length
- Blend: KPV (3 aa) + GHK-Cu (3 aa) + BPC-157 / TB-500
- Purity
- ≥ 99% (HPLC, per component)
- Published Studies
- 500+ indexed (combined literature)
- Storage
- Lyophilized: 2–8 °C, protected from light. Reconstituted: 2–8 °C, use within 30 days.
Published-study figures are approximate PubMed result counts and indicate the volume of available literature only. Purity reflects third-party analytical testing on the corresponding lot; see the Quality Assurance Center for lot-matched certificates.
Overview
KLOW is a four-component research blend combining GHK-Cu, BPC-157, TB-500, and KPV in a single lyophilized vial (80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg). Each peptide has an independent preclinical literature base spanning extracellular matrix remodeling, angiogenesis, cytoprotective signaling, and immune modulation. The blend format is used in research settings to study whether combined administration produces additive or synergistic effects across parallel tissue-repair pathways, compared with the individual peptides studied in isolation.
Citation: Pickart L., et al., International Journal of Molecular Sciences, 2018 (GHK-Cu); Sikiric P., et al., Current Pharmaceutical Design, 2018 (BPC-157)
History
Each constituent peptide has a distinct discovery history. GHK-Cu was first isolated from human plasma in 1973 and later characterized as a copper-binding tripeptide involved in wound-healing signaling and gene expression modulation. BPC-157 was identified as a stable pentadecapeptide fragment derived from a protective protein present in human gastric juice, and has since been studied extensively in rodent models of tissue injury. TB-500 is a synthetic fragment corresponding to the actin-binding region of thymosin beta-4, a naturally occurring protein involved in cell migration. KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH), studied for anti-inflammatory activity independent of the parent hormone's pigmentation effects. Multi-peptide blends like KLOW emerged from research interest in studying these complementary mechanisms concurrently rather than in isolation.
Citation: Cutuli M., et al., Journal of Leukocyte Biology, 2000 (KPV); Goldstein A.L., et al., Annals of the New York Academy of Sciences, 2012 (TB-500)
Structure
| KLOW Blend | Total Actives: 80 mg per vial |
|---|---|
| Composition | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg |
| Appearance | Lyophilized powder; may present with a blue-green hue due to the copper complex in GHK-Cu |
| Individual CAS # | GHK-Cu 89030-95-5; BPC-157 137525-51-0; TB-500 (fragment, no single CAS applies to the synthetic peptide fragment as commonly used); KPV 69630-60-0 |
| Format | Lyophilized powder |
| Purity | ≥ 99% (HPLC, per component) |
| Storage | −20 °C long term; 2–8 °C short term. Reconstituted: 2–8 °C, use within 30 days. |
Research Findings
Each component of KLOW has been studied through a distinct mechanistic lens in preclinical literature.
Key Areas of Research:
- Extracellular matrix & dermal signaling: GHK-Cu's role in upregulating collagen, elastin, and angiogenic growth-factor expression in laboratory models
- Cytoprotection & angiogenesis: BPC-157's activity across nitric-oxide signaling, growth-factor receptor modulation, and gastrointestinal and soft-tissue injury models
- Cell migration: TB-500's actin-sequestering activity and role in cell motility and blood vessel formation studies
- Immune modulation: KPV's anti-inflammatory signaling through melanocortin receptor pathways, studied in models of gut and dermal inflammation
Summary: Together, these four components give researchers a single-vial tool for studying parallel and potentially interacting tissue-repair mechanisms — matrix remodeling, cytoprotection, cell migration, and inflammation control — within one standardized research reagent. As a proprietary combination product, KLOW itself has a comparatively limited dedicated literature base; most available data concerns the individual peptide components studied separately.
Citation: Sikiric P., et al., Current Pharmaceutical Design, 2018
Source
Component literature available via PubMed — GHK-Cu, BPC-157, TB-500, and KPV mechanism research .
References
Pickart L., Margolina A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences.
Sikiric P., et al. (2018). Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design.
Goldstein A.L., Hannappel E., Sosne G., Kleinman H.K. (2012). Thymosin β4: a multi-functional regenerative peptide. Annals of the New York Academy of Sciences.
Cutuli M., Cristiani S., Lipton J.M., Catania A. (2000). Antimicrobial effects of α-MSH peptides. Journal of Leukocyte Biology.
Certificate of Analysis
Every lot is independently tested and lot-matched. View Certificates of Analysis